The estimated Net Worth of Lawrence Steinman is at least $134 Thousand dollars as of 19 December 2023. Lawrence Steinman owns over 20,000 units of BioAtla stock worth over $68,842 and over the last 21 years Lawrence sold BCAB stock worth over $65,570.
Lawrence has made over 5 trades of the BioAtla stock since 2021, according to the Form 4 filled with the SEC. Most recently Lawrence bought 20,000 units of BCAB stock worth $41,000 on 19 December 2023.
The largest trade Lawrence's ever made was buying 20,000 units of BioAtla stock on 19 December 2023 worth over $41,000. On average, Lawrence trades about 1,557 units every 63 days since 2003. As of 19 December 2023 Lawrence still owns at least 38,459 units of BioAtla stock.
You can see the complete history of Lawrence Steinman stock trades at the bottom of the page.
Lawrence's mailing address filed with the SEC is C/O BIOATLA, INC. 11085 TORREYANA ROAD, , SAN DIEGO, CA, 92121.
Over the last 4 years, insiders at BioAtla have traded over $51,913,006 worth of BioAtla stock and bought 2,491,625 units worth $40,365,176 . The most active insiders traders include Guy Levy, Asset Management, Lp Chen B..., and Jay M Phd Short. On average, BioAtla executives and independent directors trade stock every 25 days with the average trade being worth of $157,753. The most recent stock trade was executed by Sylvia Mcbrinn on 26 December 2023, trading 4,000 units of BCAB stock currently worth $9,320.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
BioAtla executives and other stock owners filed with the SEC include: